低剂量吉西他滨联合奈达铂治疗晚期非小细胞肺癌疗效观察

目的：探讨低剂量持续静脉滴注吉西他滨联合奈达铂作为晚期非小细胞肺癌的疗效、不良反应、耐受性。方法：对40例晚期非小细胞肺癌患者使用低剂量吉西他滨联合奈达铂方案化疗：吉他西滨250 mg.（m^2）^-1静滴6 h,第1、8天;奈达铂80 mg.（m^2）^-1静滴,第1天,每4周为1疗程;连续使用2个疗程后评价。结果：40例总有效率（CR＋PR）为37.5%;不良反应主要为骨髓抑制（特别是血小板下降）、外周神经毒性,但恶心和呕吐较轻。结论：低剂量持续静脉滴注吉西他滨联合奈达铂是治疗晚期非小细胞肺癌可行的化疗方案之一。

Low Dose Gemcitabine Combined Nedaplatin for Advanced Nonsmall-cell Lung Cancer: Observation of Curative Effect

OBJECTIVE： To evaluate the curative effect, toxicity and patients＇ tolerance of low dose Gemcitabine combined Nedaplatin for advanced nonsmall - cell lung cancer （NSCLC） . METHODS ： A total of 40 patients with advanced NSCLC were assigned to receive chemotherapy： Gemcitabine 250 mg.（m^2 ） ^-1 drip in 6h on the first day and 8th day, respectively, and Nedaplatin 80 mg.（m^2）^-1 drip on the first day for 2 consecutive courses （8 weeks）. RESULTS： The total effect rate （CR ＋ PR） in 40 cases was 37.5%. The drug toxicity was characterized by bone marrow depression especially the decrease of blood platelet count, peripheral neurotoxicity. The ADRs such as nausea and vomiting were mild. CONCLUSION： Low dose Gemcitabine combined Nedaplatin is a feasible therapy for advanced NSCLC.